| Cynthia Margaret Hood, OTR | |
|
418 Winter Bluff Dr, Fenton, MO 63026-6578 | |
| (636) 717-0101 | |
| Not Available |
| Full Name | Cynthia Margaret Hood |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist - Pediatrics |
| Location | 418 Winter Bluff Dr, Fenton, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235272758 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XP0200X | Occupational Therapist - Pediatrics | 2001009015 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Cynthia Margaret Hood, OTR 418 Winter Bluff Dr, Fenton, MO 63026-6578 Ph: () - | Cynthia Margaret Hood, OTR 418 Winter Bluff Dr, Fenton, MO 63026-6578 Ph: (636) 717-0101 |
News Archive
Boston Scientific Corporation announces CE Mark and European market launch of the Innova Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular lesions in arteries above the knee, specifically the superficial femoral artery (SFA) and proximal popliteal artery (PPA). The company plans to launch the product immediately in Europe and other CE Mark countries.
Practice Fusion Inc. (www.practicefusion.com), the free, web-based electronic health record (EHR) for physicians, today implemented a first-of-its-kind tool that allows its physician-users to immediately and accurately identify all Tier 1 candidates for H1N1 vaccination from their patient populations using criteria published by the Centers for Disease Control and Prevention (CDC).
The Cardiovascular Research Foundation (CRF) will present results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) at the Drug-Eluting Stent Revolution VII meeting tomorrow evening in Chicago.
An international team of researchers led by Mayo Clinic have designed a technique that uses the body's own cells and a virus to destroy cancer cells that spread from primary tumors to other parts of the body through the lymphatic system.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the unblinded results of the first of their 2 placebo-controlled double blind studies in volunteers with their anti-scarring agent RXI-109, a proprietary sd-rxRNA compound that has been shown in vitro and in animals to reduce mRNA for connective tissue growth factor.
› Verified 7 days ago
Mrs. Tessa D Forthaus, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1393 Bowles Ave, Fenton, MO 63026 Phone: 636-326-9606 | |
Elyse Nicole Wingbermuehle, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 1393 Bowles Ave, Fenton, MO 63026 Phone: 636-326-9606 | |
Mrs. Dawn Rochelle French, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 49 Winter Valley Dr, Fenton, MO 63026 Phone: 314-239-3395 | |
Mrs. Caitlin Berkbigler, MOT, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1 Arbor Ter, Fenton, MO 63026 Phone: 636-343-0016 | |
Vivi Y Radtke, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1 Arbor Ter, Fenton, MO 63026 Phone: 636-343-0016 Fax: 636-343-4794 | |
Ann M. Nusser, MS, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 58 Majestic Ct, Fenton, MO 63026 Phone: 636-225-4159 |